Purpose {#sec1}
=======

Malignant tumors are the second leading cause of deaths in the United States, and expected to surpass heart disease as the first factor leading to death \[[@cit0001]\]. In China, it is becoming one of the leading cause of deaths and an important public health issue. Among the malignant tumors, the incidence and mortality of lung cancer are the highest, followed by liver cancer, gastric cancer, and esophageal cancer \[[@cit0002]\], and they are all located in thorax and abdomen. Currently, chemotherapy, surgical resection, and radiotherapy are the standard treatment methods for malignant tumors. It is known that different treatment methods have different indications. The same tumor may have different sensibilities to different treatment methods, leading to a different therapeutic effect. Chemotherapy, such as targeted therapy, is an emerging cancer treatment and has great effectiveness for patients with advanced metastases. But the treatment effect will vary due to the unique physique of each person, and chemotherapeutic agents usually have serious side effects on the patient \[[@cit0003],[@cit0004],[@cit0005]\]. Similarly, surgical resection will bring greater trauma to the patients' body and thus cause complications to the patient \[[@cit0006],[@cit0007]\]. For a long time, radiotherapy was also one of the treatment methods for cancers because it is suitable for a variety of indications. External beam radiation was the main method of radiotherapy but it causes damage to the normal tissue around the tumor \[[@cit0008]\]. With the development of medical equipment and technology, three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), and image-guided radiation therapy (IGRT) make great achievements in cancer treatment and greatly improve the precision of radiotherapy.

^125^I seeds implantation as a form of precise radiotherapy for cancer treatment has a history of over 100 years and has been applied to various solid tumors \[[@cit0009],[@cit0010],[@cit0011],[@cit0012],[@cit0013]\]. Compared with the conventional treatment, it has three advantages. Firstly, the irradiation affects only a very localized area around the radiation sources. Exposure to radiation of healthy tissues farther away from the sources is therefore reduced. In addition, if the patient moves or if there is any movement of the tumor within the body during treatment, the radiation sources retain their correct position in relation to the tumor. These characteristics of brachytherapy provides advantages over external beam radiotherapy: the tumor can be treated with very high doses of localized radiation while reducing the probability of unnecessary damage to surrounding healthy tissues. Secondly, a permanent implantation. Once the seeds are implanted into the tumor, it can provide continuous irradiation dose. Therefore, the patient does not require multiple hospitalizations for treatment. It has been proved that ^125^I seed brachytherapy was feasible with minimal radiation-related morbidity \[[@cit0014],[@cit0015],[@cit0016]\].

In the ^125^I seed brachytherapy, the conventional coplanar template (CCT) is usually selected as a guiding tool \[[@cit0017]\]. With this template, the needles can be punctured along the planned paths. But all the needles are in a fixed direction, perpendicular to CCT. To overcome this drawback, the 3D personalized template (3DPT) was developed. It is a non-coplanar template, reconstructed from the patient computed tomography (CT) images and dose planning results. The direction of each needle can be designed more individually compared with CCT. In recent years, CCT-guided seed implantation was gradually replaced by 3DPT. Zhang *et al*. \[[@cit0018]\] successfully performed ^125^I seed implantation surgeries on thirty-one patients, with recurrent and locally advanced malignant tumors of the head and neck under the guidance of 3DPT. The research demonstrated that this approach can facilitate easier and more accurate implantation with 3DPT in clinical practice. Wang *et al*. \[[@cit0019]\] used 3DPT to perform surgeries on sixteen patients, with paravertebral and retroperitoneal malignant tumors. Similarly, Wang's group and Han's group performed ^125^I seed implantation successfully under CT guidance assisted by 3DPT for the treatment of rectal cancer, liver cancer, and cervical lymph node recurrence \[[@cit0020],[@cit0021],[@cit0022]\]. All those clinical reports have achieved great success. Therefore, ^125^I seed implantation based on 3DPT for cancer treatment is possible. However, the research about the 3DPT focuses mainly on performing clinical surgeries. To our best of knowledge, there were no related evaluations of its effectiveness and safety reported. In this research, the effectiveness and safety of ^125^I seed implantation based on a robot-assisted 3DPT were evaluated compared with that based on CCT. For this purpose, a variety of comparable surgical cases after receiving ^125^I seed brachytherapy were selected and analyzed.

Material and methods {#sec2}
====================

Patients {#sec2.1}
--------

From 2013 to 2015, 93 patients with thoracoabdominal tumors were treated, and 52 of them were eligible for robot-assisted 3D personalized template-guided ^125^I seed brachytherapy (RTDPTB). Among these 52 patients, 43 patients (82.7%) had complete information on the treatment and follow-up. Therefore, the 43 patients were involved in this analysis. For all the patients, their cancers were confirmed through CT-guided biopsy. All 43 participants treated with RTDPTB were considered as the experimental group. Meanwhile, five years before the 3DPT was applied to ^125^I seed brachytherapy, there were 108 patients who received conventional coplanar template-guided ^125^I seed brachytherapy (CCTB), among which 86 (79.6%) patients had complete information on the treatment and follow-up. Out of 86 patients, 51 with similar tumors were selected for comparison, and the 51 patients were considered as the control group. The patients' demographic and clinical characteristics are summarized in [Table 1](#t0001){ref-type="table"}. There were 27 men and 16 women, with median age of 56 years (range, 38-75) in RTDPTB. In CCTB, there were 36 men and 15 women, with median age of 58 years (range, 40-69). The Eastern Cooperative Oncology Group (ECOG) evaluation was 0-1 points in all patients.

###### 

Patient characteristics

  Characteristics                                     RTDPTB       CCTB         *p*-value
  --------------------------------------------------- ------------ ------------ -----------
  Gender                                                                        0.429
   Male                                               27 (63)      36 (70)      
   Female                                             16 (37)      15 (30)      
  Median age (range)                                  56 (38-75)   58 (40-69)   0.649
  Tumor size (cm^3^)                                                            0.772
   ≤ 30                                               19 (44)      21 (41)      
   \> 30                                              24 (56)      30 (59)      
  Diagnosis                                                                     0.723
   Lung cancer                                        8 (19)       12 (24)      
   Pancreatic cancer                                  8 (19)       10 (20)      
   Gastric cancer                                     5 (11)       7 (14)       
   Pulmonary atelectasis[\*](#tf1-1){ref-type="fn"}   3 (7)        2 (3)        
   Hepatocellular carcinoma                           8 (19)       7 (14)       
   Rectal carcinoma                                   5 (11)       6 (12)       
   Renal carcinoma                                    6 (14)       7 (13)       
  ECOG evaluation                                                               0.669
   0                                                  28 (65)      31 (61)      
   1                                                  15 (35)      20 (39)      
  Therapeutic efficacy                                                          0.016
   CR                                                 20 (47)      19 (38)      
   PR                                                 17 (39)      16 (32)      
   SD                                                 3 (7)        9 (17)       
   PD                                                 3 (7)        7 (13)       

RTDPTB -- robot-assisted 3D personalized template-guided ^125^I seed brachytherapy, CCTB -- conventional coplanar template-guided ^125^I seed brachytherapy, CR -- complete response, PR -- partial response, SD -- stable disease, PD -- progressive disease,

-- induced by lung cancer

Therapeutic method {#sec2.2}
------------------

The robot and 3DPT were developed in our laboratory. In this research, the robot achieved the accurate positioning of 3DPT and the detailed description of the robot is in reference \[[@cit0023]\]. 3DPT was created in TPS through preoperative planning and saved as "stl" format. Then, the "stl" model was imported into the 3D printing machine (Israel, Stratasys Objet30 pro). The material used for printing 3DPT is a photosensitive resin, with acrylic monomer as the main component. The printing time of a 3DPT is about 15-20 hours, depending on the size of the template. Because whether using CCT or 3DPT in a surgery, there are about two days for preoperative planning and other preparations, and 3DPT can be printed completely during this time. During these two days, no procedure was implemented, whether using CCTB or RTDPTB, so there was no impact on the treatment delivery. The advantage of 3DPT was the ability to match well with the patient's skin, as shown in [Figure 1](#f0001){ref-type="fig"}. Using 3DPT, the entry and path of needles were easily determined to avoid damage of vital structures such as large vessels. Before surgery, the low-temperature disinfection method was used to deal with 3DPT. Then, 3DPT was fixed on the end effector of the robot.

![Printed 3D personalized template matches well with the patient's skin](JCB-10-33592-g001){#f0001}

Seed implantation {#sec2.3}
-----------------

^125^I seeds used in the surgery were provided by China Institute of Atomic Energy (Beijing, China). The internal dimension of the sliver rod is 3.0 mm x 0.5 mm and the thickness of the titanium capsule is 0.05 mm. The median radioactivity of the seed was 2.59 × 10^7^ Bq or 0.7 mCi (range, 2.22--2.96 × 10^7^ Bq or 0.6-0.8 mCi) and the energy was 27-35 keV, half-life 59.4 days. Before the surgery, the radioactivity was determined using an activity meter (CRC-15).

Preimplantation preparation {#sec2.4}
---------------------------

Before the seed implantation surgery, patients received a CT scanning based on a thickness of 2.5 mm. During the CT scanning, the patient was wrapped in a negative pressure vacuum pad in order to maintain the patient's posture before surgery and remain unchanged during surgery. It should be noted that some markers were attached on the patient skin. The markers are metal balls, less than 1 mm in diameter, and the location of the marker is aligned with the laser line in the CT room. The negative pressure vacuum pad is used to maintain the patient's posture. The markers and the laser line are used to record the position of the patient on CT table. The repositioning process was completed by the markers, laser line, and the negative pressure vacuum pad. CT data was saved and exported in DICOM format.

Implantation plan {#sec2.5}
-----------------

The seed implantation plan was achieved using the Body Tumor Brachytherapy Treatment Planning System (BT-BTPS, Tianjin University, Tianjin, China), which was the latest research achievement in our laboratory. The dose calculation in BT-BTPS uses the formalism of "TG43" according to recommendations by the American Association of Physicists in Medicine \[[@cit0024],[@cit0025]\]. In this surgery, BT-BTPS will achieve the following steps \[[@cit0013]\]: 1. Read information from CT images ([Figure 2A](#f0002){ref-type="fig"}); 2. Outline gross tumor volume (GTV), clinical target volume (CTV), and planning target volume (PTV); 3. Reconstruct the tumor target and vital organs ([Figure 2B](#f0002){ref-type="fig"}); 4. Design the needle direction for seed implantation and avoid vital organs at the same time ([Figure 2C](#f0002){ref-type="fig"}); 5. Show a real-time display of the isodose line and isodose surface ([Figures 2D and 2E](#f0002){ref-type="fig"}); 6. Extract the patient's skin data to create 3DPT ([Figure 2F](#f0002){ref-type="fig"}). In step 4, when designing a needle paths, the bones and vital organs should be avoided, and interference between needles in different slices should also be eluded. Under the above conditions, it is recommendable to choose the needle path where the tumor is closer to the skin. In step 6, 3DPT was created through clipping the patient's skin. Since the positions of the tumor target and the needle were determined before, 3DPT can be guaranteed to cover the tumor target completely by clipping the skin. That is to say, 3DPT showed an advantage that it was customized according to the specific requirement of every patient, while the shape and size of CCT are unalterable. Moreover, TPS can calculate the number of seeds and needles as well as the depth of every needle. To meet the requirements of dose calculation and the dose optimization, prescription dose D~90~ was set to 110-140 Gy. In this research, the dose optimization is achieved manually using the dose--volume histogram (DVH). The DVH should meet the following conditions: V~100~ \> 90%, V~150~ \< 50%, V~200~ \< 20%. In this process, the radio-oncologist needs to adjust the position of needles and seeds repeatedly to meet those requirements.

![The steps of BT-BTPS in the ^125^I seed implantation surgery: **A)** BT-BTPS read and displayed CT images; **B)** The tumor target was segmented and reconstructed in the system; **C)** The needle directions were designed to avoid the bones and vital organs; **D)** ^125^I seeds were simulated to be implanted in the tumor along the needle paths, and the isodose (blue line) was displayed to evaluate whether the target was covered by the dose; **E)** Three-dimensional view of the implantation plan. Twentyseven non-parallel needles were designed and 72 ^125^I seeds were implanted. 100% PTV (the green area) was covered by the prescription dose (the purple area); **F)** After all needles were determined, the patient's skin was extracted from CT images and converted to the 3D printing machine](JCB-10-33592-g002){#f0002}

Therapeutic process {#sec2.6}
-------------------

The patient was placed under local anesthesia, and the needles were punctured under the guidance of 3DPT. Before the seed implantation, 3DPT was positioned and attached on the skin with the assistance of a robot. The feasible workflow of the robot in positioning the template was described as follows. In the process of template positioning, there were two positions of the template to be determined: the initial position (IP) and target position (TP), as shown in [Figure 3](#f0003){ref-type="fig"}. Firstly, the patient and the robot (3DPT was clamped on the robot) are located on the CT table. A CT scanning (1^st^ CT scanning) is performed for the patient and the template together. Secondly, CT images are transferred to BT-BTPS. The position of the template can be clearly identified in CT images and this is IP of the template. Before that, TP was determined in the preoperative planning. After the preoperative planning, we can get a template in BT-BTPS, and this position is TP. Finally, the relative position of IP and TP can be determined easily. In the template positioning, we sent the relative position of IP and TP to the robot, and the template can be moved from IP to TP.

![The process to get the initial position and target position](JCB-10-33592-g003){#f0003}

In the template positioning process above, a new technology was involved. It is easy to find that IP is in the actual space, and TP is in the image space. The problem that needs to be solved is how to unify the positions of these two spaces into the same space. In this research, the relative position of the robot and the patient was kept unchanged, and a CT scanning was performed for the patient and the template (fixed on the end effector of the robot) together. Thus, IP and TP were all in the image space. It is easy to get the relative position of IP and TP in BT-BTPS, and control the robot to move the template from IP to TP.

During the surgery, the doctor inserted needles through the guiding holes on the template. Next, ^125^I seeds were implanted in the tumor target through the needles. The seed positions in the needle were calculated in the BT-BTPS, and the seeds interval in the same needle was at least 1.0 cm. Standardized treatment was carried out after the seed implantation surgery to prevent bleeding and infection.

Therapeutic evaluation {#sec2.7}
----------------------

### Post-operative validation {#s2g1}

After implanting all seeds, a CT scanning was performed to verify whether the seeds were in the expected position. The CT images after implantation were imported to BT-BTPS. The radio-oncologist outlined the tumor target and identified all the seeds in CT images, so that the seeds could be clearly observed in three dimensions. Through displaying the isodose line, it could be observed, whether the PTV has been covered by the prescription dose. The actual dose distribution in the tumor target was evaluated using DVH. The DVH was compared with the implantation plan.

### DVH evaluation {#s2g2}

In this research, conformity index (CI) \[[@cit0026],[@cit0027]\] and homogeneity index (HI) \[[@cit0028]\] were analyzed to establish their association with OS and LC. CI and HI were calculated using the DVH in the post-operative validation and the formulas were shown in Eq. ([1](#eq1){ref-type="disp-formula"}) and Eq. ([2](#eq2){ref-type="disp-formula"}).
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Where *V~T~* was the total volume of the GTV; *V*~ref~ was the total volume covered by the prescription dose isodose surface; *V~T,~*~ref~ was the total volume of the GTV covered by the prescription dose isodose surface; *D*~2~ was the dose received by 2 percent of the GTV, regarded as the maximal dose; *D*~98~ was the dose received by 98 percent of the GTV, regarded as the minimal dose; *D*~ref~ was the prescription dose in this plan.

Follow-up and statistical analysis {#sec2.8}
----------------------------------

Follow-up was carried out every two months for the first year and every 6 months thereafter, including CT scanning, physical examination, and radiography. The changes in tumor size can be evaluated using the CT images. In this paper, the response evaluation criteria in solid tumors (RECIST) was used to evaluate the target lesions \[[@cit0029]\]. In this response, criteria were defined as: complete response (CR: disappearance of all target lesions); partial response (PR: at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter); stable disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest diameter since the treatment started); progressive disease (PD: at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions). The recurrence mostly occurs within 2 years after the surgery and the diagnosis was confirmed by histopathology whenever required. Overall survival (OS) was calculated as the interval between the date of ^125^I seed brachytherapy and that of death, and if the patient was still alive, OS was censored by the last follow-up data. Local control (LC) was calculated from the date of ^125^I seed brachytherapy to the recurrence. OS and LC were estimated by the Kaplan-Meier method using the statistical product and service solutions (SPSS) 25.0 for Windows. The Cox regression was used to analyze the association of OS and LC with other factors. Significant association was confirmed when *p* \< 0.05.

Ethical approval of the study protocol {#sec2.9}
--------------------------------------

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All patients provided written informed consent to participate in this study.

Results {#sec3}
=======

Outcome of seed implantation {#sec3.1}
----------------------------

In every surgery, the implantation plan, positioning of 3DPT, seed implantation, and post-operative validation were completely achieved. The median PTV was 35.21 cm^3^ (range, 14.36-102.35). Six to eighteen needles (median, 10) and 27-72 seeds (median, 35) were involved in every surgery to achieve the prescription dose of 110-140 Gy (median, 120 Gy). The time spent on each surgery ranged from 35-51 minutes (median, 42 minutes), while it spent 65-96 minutes (median, 78 minutes) using CCT. The steps of a surgery included CT scanning, positioning of a template, implantation of needles and seeds, and post-operative validation, excluding the preoperative planning and printing 3DPT. Therefore, the surgery time recorded in this research included the time spent on CT scanning, positioning of a template, implantation of needles and seeds, and post-operative validation. In the post-operative validation, the median dosimetry information were as follows: V~100~ was 95.3% (range, 92.4-109.8) and D~90~ was 126.1 Gy (range, 114.2-132.0). All the treatment parameters were summarized in [Table 2](#t0002){ref-type="table"}, including information about CCTB.

###### 

Treatment parameters

  Parameter                RTDPTB                 CCTB
  ------------------------ ---------------------- ----------------------
  PTV (cm^3^)              35.21 (14.36-102.35)   40.34 (12.05-115.46)
  PD (Gy)                  120 (110-140)          120 (110-140)
  D~90~ (Gy)               126.1 (114.2-132.0)    116.4 (105.1-145.7)
  V~100~ (% PTV)           95.3 (92.4-109.8)      90.3 (87.6-115.6)
  No. of seeds             35 (27-72)             31 (23-68)
  No. of needles           10 (6-18)              13 (7-20)
  Seed activity (mCi)      0.7 (0.6-0.8)          0.7 (0.6-0.8)
  Time per surgery (min)   42 (35-51)             78 (65-96)
  CI                       0.93 (0.89-0.96)       0.78 (0.69-0.92)
  HI                       2.97 (2.18-6.51)       5.46 (3.25-10.36)

RTDPTB -- robot-assisted 3D personalized template-guided ^125^I seed brachytherapy, CCTB -- conventional coplanar template-guided ^125^I seed brachytherapy, PTV -- planning target volume, PD -- prescription dose, D~90~ -- the minimum dose covering 90% of the target volume, V~100~ -- the target volume treated by the prescription dose, min -- minute, CI -- conformity index, HI -- homogeneity index

Treatment effectiveness {#sec3.2}
-----------------------

The median follow-up time was 23 months (range, 8-42) and 25 months (range, 8-48) in RTDPTB and CCTB, respectively. The overall treatment effectiveness for all patients was collected and evaluated. In RTDPTB, the median OS was 30 months (95% confidence interval: 11.8-40.2), the median LC was 33 months (95% confidence interval: 28.6-37.4), and the 2-year OS and LC rates were 58.1% and 86.0%, respectively. In CCTB, the median follow-up time was 25 months (range, 8-48). The median OS was 20 months (95% confidence interval: 15.5-24.4), the median LC was 33 months (95% confidence interval: 19.1-46.9), and the 2-year OS and LC rates were 39.2% and 62.7%, respectively. Considering that the mixed tumor population can influence the accuracy and scientificity of the statistics, the treatment effectiveness for each kind of tumor type was summarized separately, including 2-year OS and LC rates, median OS and LC ([Table 3](#t0003){ref-type="table"}).

###### 

Treatment effectiveness for each kind of tumor type (RTDPTB/CCTB)

  Tumor type                                         2-year OS rate   2-year LC rate   MOS (month)   MLC (month)
  -------------------------------------------------- ---------------- ---------------- ------------- -------------
  Lung cancer                                        62.5%/41.7%      75.0%/58.3%      34/22         36/28
  Pancreatic cancer                                  50.0%/30.0%      62.5%/50.0%      28/20         29/26
  Gastric cancer                                     60.0%/28.6%      80.0%/42.8%      30/18         31/20
  Pulmonary atelectasis[\*](#tf3-1){ref-type="fn"}   66.7%/50.0%      100.0%/50.0%     32/20         38/29
  Hepatocellular carcinoma                           62.5%/42.8%      75.0%/57.1%      31/22         34/26
  Rectal carcinoma                                   40.0%/33.3%      60.0%/50.0%      23/18         29/24
  Renal carcinoma                                    66.7%/42.8%      83.3%/57.1%      30/18         38/26

OS -- overall survival, LC -- local control, MOS -- median overall survival, MLC -- median local control, RTDPTB -- robot-assisted 3D personalized template-guided ^125^I seed brachytherapy, CCTB -- conventional coplanar template-guided ^125^I seed brachytherapy,

-- induced by lung cancer

The therapeutic efficacy of RTDPTB through the follow-up process is summarized in [Table 1](#t0001){ref-type="table"}, and some typical cases are shown in [Figure 4](#f0004){ref-type="fig"}. Among the 43 patients, 20 (47%) patients achieved CR, 17 (39%) PR, 3 (7%) SD, and 3 (7%) PD, while there were 19 (38%) CR, 16 (32%) PR, 9 (17%) SD, and 7 (13%) PD in the 51 patients of CCTB.

![Computed tomography images of some typical cases. **Case 1: 1A**) the seeds distribution after brachytherapy of a 50-yearold female with renal carcinoma; **1B**) There were bones surrounding the tumor, so 3DPT was used instead of CCT. Along the two arrows, the different directions of needle could be clearly observed; **1C**) Two months after brachytherapy, the tumor was significantly decreased, and the seeds gathered together. **Case 2: 2A**) a 60-year-old patient with pelvic cancer received ^125^I seed brachytherapy under the guidance of 3DPT. The needle reached the tumor target through the gap of bones; **2B**) The seeds were distributed throughout the tumor volume after brachytherapy; **2C**) Six months after ^125^I seed brachytherapy, the tumor nearly disappeared. **Case 3: 3A**) A 51-year-old patient was diagnosed with lung cancer and it was surrounded by ribs. Hence, 3DPT was chosen to guide the surgery; **3B**) The seeds distribution was displayed after ^125^I seed brachytherapy; **3C**) One month after the surgery, the tumor size has significantly decrease](JCB-10-33592-g004){#f0004}

Analysis of factors associated with overall survival and local control {#sec3.3}
----------------------------------------------------------------------

In RTDPTB, median CI and HI were 0.93 (range, 0.89-0.96) and 2.97 (range, 2.18-6.51), respectively. While in the other reference method, they were 0.78 (range, 0.69-0.92) and 5.46 (range, 3.25-10.36), respectively. Besides, we analyzed the following covariates associated with OS and LC: age, gender, and tumor size. The results of the association analysis are summarized in [Table 4](#t0004){ref-type="table"}. The results demonstrated that CI (≤ or \> 0.9) and HI (≤ or \> 4) were significant factors in OS and LC (*p* \< 0.05). And there were no association of OS and LC with other factors (age, gender, and tumor size).

###### 

Results of association analysis

  Factor                               *p*-value   
  ------------------------------------ ----------- -------
  Age, year (≤ 60 vs. \> 60)           0.109       0.095
  Gender (male vs. female)             0.153       0.168
  Tumor size, cm^3^ (≤ 30 vs. \> 30)   0.071       0.067
  Approach (3DPT vs. CCT)              0.009       0.010
  CI (≤ 0.9 vs. \> 0.9)                0.009       0.006
  HI (≤ 4 vs. \> 4)                    0.008       0.006

OS -- overall survival, LC -- local control, CI -- conformity index, HI -- homogeneity index

Complications {#sec3.4}
-------------

For all patients, surgeries were performed successfully without massive bleeding during or after the surgery. Other complications related to the procedure that occurred during or after the surgery were analyzed. In CCTB, three patients were detected with small local hematomas (one in lung, one in pelvic cavity, and one in kidney) after inserting the needle, probably because of the injured small blood vessels. Two patients presented pneumothorax caused by coplanar puncture damage to lung tissue and recovered after drainage. In RTDPTB, one patient had a small local hematoma in lung, and the symptom disappeared after symptomatic treatment. There were no severe radiation-related complications such as radioactive inflammation. The radiation-related complications as per the Radiation Therapy Oncology Group (RTOG) grading are summarized in [Table 5](#t0005){ref-type="table"}. In CCTB, there were five patients presented fever symptoms, four of grade 1 and one of grade 2, and three patients were detected with leucopenia of grade 1. However, in RTDPTB, there were two patients presented fever symptoms of grade 1, and two patients were detected with grade 1 leucopenia. All those symptoms disappeared in two days after symptomatic treatment.

###### 

Radiation-related complications and RTOG grade

  Grade                       Grade 0 (RTDPTB/CCTB)   Grade 1 (RTDPTB/CCTB)   Grade 2 (RTDPTB/CCTB)
  --------------------------- ----------------------- ----------------------- -----------------------
  Acute complications                                                         
   Fever                      41 (95.4%)/46 (90.2%)   2 (4.6%)/4 (7.8%)       0 (0%)/1 (2.0%)
   Leucopenia                 41 (95.4%)/48 (94.1%)   2 (4.6%)/3 (5.9%)       0 (0%)/0 (0%)
   Radioactive inflammation   43 (100%)/51 (100%)     0 (0%)/0 (0%)           0 (0%)/0 (0%)
  Late complications                                                          
   Subcutaneous tissue        43 (100%)/51 (100%)     0 (0%)/0 (0%)           0 (0%)/0 (0%)

RTOG -- Radiation Therapy Oncology Group, RTDPTB -- robot-assisted 3D personalized template-guided ^125^I seed brachytherapy, CCTB -- conventional coplanar template- guided ^125^I seed brachytherapy

Discussion {#sec4}
==========

As of now, few articles report on the effectiveness and safety of robot-assisted 3DPT-guided ^125^I seed implantation. The aim of this work was the attempt to fill this gap. In order to obtain an accurate assessment, we selected as many cases as possible over a long period of time as well as a long follow-up. Finally, in RTDPTB, 43 patients with thoracoabdominal tumors were selected. Meanwhile, in CCTB, 51 patients with similar tumors were selected as reference. The patient characteristics in RTDPTB and CCTB were analyzed using SPSS. The results demonstrated that there were no significant differences in characteristics between the two groups, including gender, age, tumor size, diagnosis, and ECOG evaluation (*p* \> 0.05, [Table 1](#t0001){ref-type="table"}). Therefore, the comparison between RTDPTB and CCTB was significative.

For treatment of malignant tumors, a good effectiveness is mainly reflected in achieving an effective local control of the tumor and prolonging the survival time after a rationalized treatment. In order to evaluate this, OS and LC of RTDPTB were compared with that of CCTB. For different tumor type, the patients' OS and LC maybe different. In order to improve the comparability, different tumor types were classified and compared between RTDPTB and CCTB ([Table 3](#t0003){ref-type="table"}). However, the results demonstrated that the 2-year OS and LC rates of RTDPTB increased (18.9% and 23.3%, respectively) compared with that of CCTB, respectively, in the mixed tumor population. Statistical analysis showed that there was significant difference in 2-year OS (*p* = 0.015 \< 0.05) and LC (*p* = 0.007 \< 0.05), respectively. For classified population according to the tumor type, taking the lung cancer for example, the 2-year OS and LC rates (62.5% and 75%, respectively) of RTDPTB increased 20.8% and 16.7% compared with that (41.7% and 58.3%, respectively) of CCTB, respectively. Statistical analysis showed that there was significant difference in 2-year OS (*p* = 0.030 \< 0.05) and LC (*p* = 0.025 \< 0.05), respectively. The trend is also observed in other tumor types. Furthermore, the OS and LC rates of CCTB declined more quickly in the first two years after surgery ([Figure 5](#f0005){ref-type="fig"}), indicating that RTDPTB was more effective in the treatment of thoracoabdominal tumors.

![Kaplan-Meier analysis of overall survival and local control in RTDPTB and CCTB: **A)** Overall survival rate of the two methods; **B)** Local control rate of the two methods; **C)** Overall survival rate of the two methods in the treatment of lung cancer; **D)** Local control rate of the two methods in the treatment of lung cancer](JCB-10-33592-g005){#f0005}

Through the comprehensive association analysis, CI (*p*-value: 0.009 and 0.006 for OS and LC, respectively), HI (*p*-value: 0.008 and 0.006), and guidance approach (*p*-value: 0.009 and 0.010) were significant factors in OS and LC (*p* \< 0.05, [Table 4](#t0004){ref-type="table"}). Moreover, CI and HI in RTDPTB improved (19.2% and 45.6%, respectively) than that of CCTB (CI, 0.93 and 0.78 for RTDPTB and CCTB, respectively; HI, 2.97 and 5.46, respectively) ([Table 2](#t0002){ref-type="table"}). Statistical analysis showed that between RTDPTB and CCTB there was significant difference in CI (*p* = 0.000 \< 0.05) and HI (*p* = 0.000 \< 0.05). No surprisingly, in CCTB, some regions of the tumor target cannot receive adequate radiation dose, leading to a poor local control and effectiveness. This was further conformed through DVH analysis. Under the guidance of 3DPT, the DVH of post-operative validation was almost identical to the implantation plan ([Figure 6A](#f0006){ref-type="fig"}). However, there was a large deviation between the two DVHs whenever using CCT ([Figure 6B](#f0006){ref-type="fig"}). To make a more comprehensive discussion, CI and HI of pre- and post-operation were also calculated and compared. In RTDPTB, the pre- and post-operation CI were both 0.95, and the pre- and post-operation HI were 1.91 and 2.02, respectively. In CCTB, the pre- and post-operation CI were 0.95 and 0.91, and the pre- and post-operation HI were 4.58 and 6.45, respectively. Obviously, CI and HI were almost the same in pre- and post-operation in RTDPTB, while there were significant differences in CCTB. The result indicated that the implantation plan could be much more effectively realized by using robot-assisted 3DPT. Based on this outcome, the tumor was effectively controlled, and survival time was lengthened.

![The comparison of DVHs between implantation plan (red line) and post-operative validation (green line) of one patient. **A)** DVHs in RTDPTB. Pre-operation CI and HI: 0.95 and 1.91; post-operation CI and HI: 0.95 and 2.02. **B)** DVHs in CCTB. Pre-operation CI and HI: 0.95 and 4.58; post-operation CI and HI: 0.91 and 6.45](JCB-10-33592-g006){#f0006}

To get a more comprehensive and reliable evaluation of effectiveness between RTDPTB and CCTB, several studies based on CCTB reported in the literature were also analyzed \[[@cit0029],[@cit0030],[@cit0031],[@cit0032],[@cit0033],[@cit0034],[@cit0035],[@cit0036]\]. The relevant information was summarized in [Table 6](#t0006){ref-type="table"}. Median survival time ranged from 7 to 22 months, and the 2-year OS rates were 10.7-52%. In our research with favorable outcomes, the median OS was 30 months and 2-year OS rate was 58.1%. Through comparative analysis, for every kind of tumor type, the 2-year OS rate of RTDPTB was higher than that reported in the relevant literature. These findings indicated that ^125^I seed implantation under the guidance of robot-assisted 3DPT was more effective than that of CCT.

###### 

Comparison of present research with other studies

  Authors                         Tumor type                                         Number of patients   MST (month)   2-year OS rate/present research
  ------------------------------- -------------------------------------------------- -------------------- ------------- ---------------------------------
  Wang *et al*. \[[@cit0030]\]    Pancreatic cancer                                  31                   7             25.81%^a^/87.5%^a^
  Liu *et al*. \[[@cit0031]\]     Pancreatic cancer                                  30                   16            40%/50%
  Shi *et al*. \[[@cit0032]\]     Gastric cancer                                     28                   22            52%/60%
  Huo *et al*. \[[@cit0033]\]     Lung cancer                                        38                   21            47.4%/62.5%
  Zhang *et al*. \[[@cit0034]\]   Hepatocellular carcinoma                           27                   13.5          30.8%/62.5%
  Wang *et al*. \[[@cit0035]\]    Rectal carcinoma                                   15                   10            10.7%/40%
  Karam *et al*. \[[@cit0036]\]   Lung cancer                                        16                   --            78%^a^/100%^a^
  Lu *et al*. \[[@cit0037]\]      Pulmonary atelectasis[\*](#tf6-1){ref-type="fn"}   15                   16            13.3%/66.7%

MST -- median survival time, OS -- overall survival, ^a^ -- one-year OS rate,

-- induced by lung cancer

The success of ^125^I seed brachytherapy depends on the accurate placement of radioactive seeds within the tumor target. When using CCTB for the treatment of cancer, there are several unsafe aspects. On one side, irradiation damage to normal tissues around the tumor target may be induced due to the lower CI, which was discussed above. On the other side, all the parallel needle directions were perpendicular to the template. That means, once the CCT was fixed, the needle direction was determined as well. The needle direction cannot be changed to avoid some vital organs. Only when the bones were thinner, they could be drilled to ensure the needles to pass. Otherwise, the implantation plans have to be given up, where there were vital organs or bones blocking the way. Therefore, the application of CCT would lead to a certain risk and limitations. Instead, the application of 3DPT had solved this problem and enhanced the safety. The needle could reach the expected position along a safe path through rotating a certain angle. In addition, 3DPT was produced exactly according to the patient's skin, so it can be completely matched with the skin and reduce the difficulty in positioning. Hence, using 3DPT can meet the requirements for various tumor locations under safe conditions.

To better evaluate the safety of these two methods, the complications were collected and analyzed ([Table 5](#t0005){ref-type="table"}). The incidence of radiation-related complications in RTDPTB (4.6% fever, 4.6% leucopenia, and 0% radioactive inflammation) was lower than in CCTB (9.8% fever, 5.9% leucopenia, and 0% radioactive inflammation). And there were no late complications observed during follow-up period. The risk of damaging vital blood vessels and organs can be greatly minimized in RTDPTB. Integrating the previous analysis, in can be demonstrated that RTDPTB can achieve a good safety.

In addition, ^125^I seed implantation surgery with CCT takes usually 78 minutes, while it takes only 42 minutes using robot-assisted 3DPT. It was also an indicator in the evaluation of safety. For ^125^I seed brachytherapy, long time spent on surgery indicated great damage to the patient. There may be two reasons: 1. CCT positioning is difficult and repeated CT scanning was time consuming and harmful to the patient; 2. Drilling holes on the thin rib would consume a lot of time, and it also causes damage to patient. Consequently, the less time-consuming process in RTDPTB reached a better safety.

In the end, the dose planning and dose optimization of these cases in this research were achieved manually, not by automatic inverse planning. Therefore, it will have a certain impact on the results between RTDPTB and CCTB caused by manual planning and optimizing. In this research, we have tried to reduce this impact. In the final dose optimization, in addition to meeting the basic conditions (V~100~ \> 90%, V~150~ \< 50%, V~200~ \< 20%), we tried to choose the solution that makes the DVH optimal. At present, the automatic inverse optimization has been achieved. In the future work, we will eliminate the interference of manual planning to more accurately evaluate the effectiveness and safety of RTDPTB.

Conclusions {#sec5}
===========

Through our research and comparisons with other studies, robot-assisted 3DPT shows sufficient effectiveness and safety in ^125^I seed brachytherapy for the treatment of thoracoabdominal tumors. It is proved to be more effective, better tolerated, and less time-consuming. This research was based on a small number of patients and relatively short follow-up time. Hence, a larger patient cohort and longer follow-up periods should be involved to reach a more definite conclusion in the future research.
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